PacBio announced management participation in two investor conferences and will provide live webcasts of the events.
Quiver AI Summary
PacBio, a leader in high-quality sequencing solutions, announced its participation in two upcoming investor conferences: the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, in Boston, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, 2025, in New York. These events will be accessible via live webcasts on the company's investor page, with replays available for at least 30 days afterwards. PacBio specializes in advanced sequencing technologies that assist researchers in tackling complex genetic challenges across various fields, including human genomics and oncology. Additional information is available on their website.
Potential Positives
- PacBio is participating in prominent investor conferences, which can enhance company visibility and attract potential investors.
- Live webcasts and availability of replays indicate transparency and engagement with the investor community.
- The mention of advanced sequencing solutions positions PacBio as a leader in a growing field, appealing to stakeholders interested in innovative technologies.
Potential Negatives
- While the company is participating in investor conferences, there is no indication of significant new developments or product announcements, which may lead to perceptions of stagnation or lack of innovation.
- The press release emphasizes that their products are for Research Use Only, indicating limitations in their application for diagnostics, which may hinder their market competitiveness.
FAQ
When will PacBio participate in investor conferences?
PacBio will participate in the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, 2025.
How can I access the webcasts of the events?
Webcasts of the events can be accessed at the company's investors page at investor.pacificbiosciences.com.
Will there be a replay of the webcasts?
Yes, a replay of the webcasts will be available for at least 30 days following each event.
What types of solutions does PacBio provide?
PacBio offers advanced sequencing solutions for human germline sequencing, plant and animal sciences, infectious disease, oncology, and more.
Is PacBio's sequencing technology available for diagnostic use?
No, PacBio products are provided for Research Use Only and are not intended for diagnostic procedures.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PACB Insider Trading Activity
$PACB insiders have traded $PACB stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $PACB stock by insiders over the last 6 months:
- CHRISTIAN O HENRY (See Remarks) has made 0 purchases and 2 sales selling 272,406 shares for an estimated $505,692.
- OENE MARK VAN (See Remarks) has made 0 purchases and 2 sales selling 107,259 shares for an estimated $198,377.
- MICHELE FARMER (See Remarks) has made 0 purchases and 3 sales selling 32,517 shares for an estimated $55,110.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PACB Hedge Fund Activity
We have seen 81 institutional investors add shares of $PACB stock to their portfolio, and 119 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC removed 14,861,287 shares (-87.1%) from their portfolio in Q1 2025, for an estimated $17,536,318
- GOLDMAN SACHS GROUP INC removed 2,928,293 shares (-61.1%) from their portfolio in Q1 2025, for an estimated $3,455,385
- MORGAN STANLEY removed 2,279,826 shares (-40.3%) from their portfolio in Q1 2025, for an estimated $2,690,194
- WALLEYE CAPITAL LLC removed 1,943,046 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $2,292,794
- JACKSON SQUARE PARTNERS, LLC removed 1,788,905 shares (-35.0%) from their portfolio in Q1 2025, for an estimated $2,110,907
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,510,812 shares (-85.3%) from their portfolio in Q1 2025, for an estimated $1,782,758
- SOROS FUND MANAGEMENT LLC removed 1,372,265 shares (-57.8%) from their portfolio in Q1 2025, for an estimated $1,619,272
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PACB Analyst Ratings
Wall Street analysts have issued reports on $PACB in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stephens & Co. issued a "Overweight" rating on 05/15/2025
- Canaccord Genuity issued a "Buy" rating on 04/10/2025
- Scotiabank issued a "Sector Outperform" rating on 03/25/2025
To track analyst ratings and price targets for $PACB, check out Quiver Quantitative's $PACB forecast page.
$PACB Price Targets
Multiple analysts have issued price targets for $PACB recently. We have seen 6 analysts offer price targets for $PACB in the last 6 months, with a median target of $1.65.
Here are some recent targets:
- Luke Sergott from Barclays set a target price of $1.5 on 06/25/2025
- David Westenberg from Piper Sandler set a target price of $1.25 on 05/15/2025
- Mason Carrico from Stephens & Co. set a target price of $1.8 on 05/15/2025
- Kyle Mikson from Canaccord Genuity set a target price of $3.0 on 04/10/2025
- Sung Ji Nam from Scotiabank set a target price of $2.0 on 03/25/2025
- Matthew Sykes from Goldman Sachs set a target price of $1.5 on 02/18/2025
Full Release
MENLO PARK, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences:
- Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, at 2:30 PM ET in Boston, MA
- Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10, 2025, at 12:20 PM ET in New York, NY
Live webcasts of the events can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcasts will be available for at least 30 days following the event.
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Contacts
Investors:
Todd Friedman
[email protected]
Media:
[email protected]